Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus OXYBUTYNIN CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus OXYBUTYNIN CHLORIDE.
CANTIL vs OXYBUTYNIN CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Oxybutynin chloride is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), leading to relaxation of the detrusor muscle and reduction of urinary bladder contractions.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (100 mg) applied once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 12–13 hours in plasma; clinical effect may persist longer due to active metabolite (N-desethyloxybutynin, half-life ~12–13 hours).
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily hepatic metabolism; <0.1% excreted unchanged in urine. Metabolites (e.g., N-desethyloxybutynin) excreted mainly renally. Fecal elimination <0.02%.
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic